CG Oncology, Inc. SEC filings CGON
CG Oncology, Inc. has 243 filings in SEC EDGAR's recent list, going back to Oct 27, 2023. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 6, 2026 (results of operations, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 6, 2026 | Aug 6, 2026 |
| 424B5 | Prospectus supplement | Aug 6, 2026 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Officer or director change
|
May 26, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 8, 2026 | May 8, 2026 |
| ARS | Annual report to shareholders | Apr 24, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 24, 2026 | — |
| DEF 14A | Proxy statement | Apr 24, 2026 | Apr 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 13, 2026 | Apr 13, 2026 |
| S-8 | Employee stock plan registration | Feb 27, 2026 | — |
| 10-K | Annual report | Feb 27, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2026 | Feb 27, 2026 |
| 8-K |
Current report
Other events
|
Jan 13, 2026 | Jan 13, 2026 |
| 424B5 | Prospectus supplement | Jan 13, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 9, 2026 | Jan 9, 2026 |
| 8-K |
Current report
Officer or director change
|
Nov 26, 2025 | Nov 22, 2025 |
| 8-K |
Current report
Officer or director change
|
Nov 14, 2025 | Nov 10, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2025 | Nov 14, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2025 | Sep 9, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 5, 2025 | Sep 5, 2025 |
| 10-Q | Quarterly report | Aug 8, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2025 | Aug 8, 2025 |
| 8-K |
Current report
Officer or director change
|
Jul 11, 2025 | Jul 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 6, 2025 | Jun 5, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 28, 2025 | Apr 26, 2025 |
| ARS | Annual report to shareholders | Apr 25, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 5, 2025 |
| S-3ASR | Automatic shelf registration | Mar 28, 2025 | — |
| 10-K | Annual report | Mar 28, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2025 | Mar 28, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 24, 2025 | Mar 24, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 10, 2025 | Jan 9, 2025 |
| 424B4 | Prospectus | Dec 13, 2024 | — |
| EFFECT | Filing | Dec 12, 2024 | — |
| S-1/A | Amended registration statement | Dec 11, 2024 | — |
| CORRESP | Letter to the SEC | Dec 11, 2024 | — |
| CORRESP | Letter to the SEC | Dec 11, 2024 | — |
| S-1 | Registration statement | Dec 11, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 5, 2024 | Dec 5, 2024 |
| UPLOAD | Letter from the SEC | Nov 21, 2024 | — |
| DRS | Filing | Nov 14, 2024 | — |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 24, 2024 | May 24, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Other events
|
May 3, 2024 | May 3, 2024 |
| 10-K | Annual report | Mar 26, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Officer or director change
|
Feb 16, 2024 | Feb 15, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Jan 30, 2024 | Jan 29, 2024 |
| SEC STAFF LETTER | Filing | Jan 26, 2024 | — |
| S-8 | Employee stock plan registration | Jan 26, 2024 | — |
| 424B4 | Prospectus | Jan 25, 2024 | — |
| EFFECT | Filing | Jan 24, 2024 | — |
| S-1MEF | Filing | Jan 24, 2024 | — |
| CERT | Filing | Jan 24, 2024 | — |
| S-1/A | Amended registration statement | Jan 23, 2024 | — |
| CORRESP | Letter to the SEC | Jan 22, 2024 | — |
| CORRESP | Letter to the SEC | Jan 22, 2024 | — |
| 8-A12B | Filing | Jan 22, 2024 | — |
| S-1/A | Amended registration statement | Jan 18, 2024 | — |
| CORRESP | Letter to the SEC | Jan 5, 2024 | — |
| CORRESP | Letter to the SEC | Jan 2, 2024 | — |
| S-1 | Registration statement | Jan 2, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2023 | — |
| DRSLTR | Filing | Dec 4, 2023 | — |
| DRS/A | Filing | Dec 4, 2023 | — |
| SEC STAFF LETTER | Filing | Nov 27, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 27, 2023 | — |
| DRS | Filing | Oct 27, 2023 | — |
Showing 78 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CGON (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Dallas, TX
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1991792
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.